<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00024076</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068889</org_study_id>
    <secondary_id>P30CA016042</secondary_id>
    <secondary_id>UCLA-9908024</secondary_id>
    <secondary_id>NCI-G01-2011</secondary_id>
    <nct_id>NCT00024076</nct_id>
  </id_info>
  <brief_title>Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer</brief_title>
  <official_title>Radiofrequency Ablation of Pulmonary Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells.
      CT-guided radiofrequency ablation may be effective treatment for lung cancer.

      PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating
      patients who have refractory or advanced lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the safety and toxicity of radiofrequency ablation in patients with refractory
           or advanced pulmonary malignancies.

        -  Determine the efficacy of this treatment, in terms of local control, in these patients.

        -  Determine whether CT scan is a reasonable imaging assessment tool for treatment delivery
           and follow-up in these patients.

      OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the
      tumor over 2 hours.

      Patients are followed at 1, 3, 6, and 12 months.

      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">30</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Malignant Mesothelioma</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Thymoma and Thymic Carcinoma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiofrequency ablation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of a primary or secondary intrathoracic malignancy

               -  Any cell type or origin

               -  Involving the intrapulmonary, mediastinal, or pleural/chest wall

               -  Inoperable primary or metastatic cancer to the lung

          -  Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy, or
             radiotherapy)

          -  Single or multiple lesions that are non-contiguous with vital structures or organs
             such as:

          -  Trachea

          -  Heart

          -  Aorta

          -  Great vessels

          -  Esophagus

          -  Less than 5 cm in largest dimension

          -  Accessible via percutaneous transthoracic route

          -  Hepatic:

               -  Coagulation profile normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert D. Suh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>October 28, 2015</last_update_submitted>
  <last_update_submitted_qc>October 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>recurrent malignant mesothelioma</keyword>
  <keyword>recurrent thymoma and thymic carcinoma</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>pulmonary carcinoid tumor</keyword>
  <keyword>lung metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Thymoma</mesh_term>
    <mesh_term>Thymus Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

